Cabaletta Bio (NASDAQ:CABA) posted its earnings results on Sunday. The company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.05, MarketWatch Earnings reports.
Shares of CABA stock traded down $0.35 on Tuesday, hitting $10.37. The stock had a trading volume of 6,056 shares, compared to its average volume of 107,644. The business has a 50 day moving average of $11.09 and a 200 day moving average of $12.49. The stock has a market cap of $208.89 million, a price-to-earnings ratio of -7.27 and a beta of 1.67. Cabaletta Bio has a 12-month low of $6.35 and a 12-month high of $16.38.
A number of equities research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Cabaletta Bio from a “buy” rating to a “hold” rating in a research note on Monday, January 4th. Chardan Capital reiterated a “buy” rating and set a $21.00 target price on shares of Cabaletta Bio in a research report on Friday, January 8th. Finally, HC Wainwright boosted their target price on shares of Cabaletta Bio from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, March 23rd.
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
Recommended Story: Arbitrage
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.